[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
May 1, 2002

Varicella Vaccine and Shingles—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;287(17):2211-2212. doi:10.1001/jama.287.17.2209

In Reply: We agree with Dr Brisson and colleagues that surveillance for HZ is essential for evaluating the impact of the varicella vaccination program. Because the population sizes in the varicella active surveillance sites are not sufficient to monitor age-specific HZ incidence, the CDC has funded 2 other sites—Massachusetts Department of Public Health and Group Health Cooperative (GHC) in Seattle—to conduct population-based varicella and HZ surveillance and monitor age-specific incidence rates. Massachusetts has monitored incidence through a statewide telephone survey since 1998,1 while GHC is examining its automated medical records since 1992. To date, no increase in HZ is evident in any age group in either site (CDC, unpublished data, 2001).2 However, continued surveillance is needed to detect any changes in HZ incidence.

First Page Preview View Large
First page PDF preview
First page PDF preview
×